To guide the development of clinical treatment strategies, we screened tyrosine kinase inhibitors, mTOR inhibitors, and histone deacetylase (HDAC) inhibitors from the pRRophetic package to assess their association with ccRCC resistance. The gene discussed is HDAC9; the disease is nonpapillary renal cell carcinoma.